Long-term cost-effectiveness of health behaviour intervention to manage type 2 diabetes in Nepal

Table 1 Input parameters for the cost-effectiveness analysis

Input parameters	Intervention	Control	Distribution	Sources
Age in Mean (SD)	54.26 (9.12)	54.62 (9.71)	Log-normal	[26]
Transition probability
Pre-diabetes to T2DM (1 to 2)	0.04	0.10	Normal	[25]
Pre-diabetes to death (1 to 4)	0.014	0.014	Normal	[27]
T2DM to complication (2 to 3)^a	0.13	0.34	Normal	[26, 28]
T2DM to death (2 to 4)	0.004	0.02	Normal	[26]
Complication** to death (3 to 4)^a	0.01	0.01	Normal	[26]
Relative risk
Pre-diabetes	0.46	na	Normal	[25]
T2DM	0.88	na	Normal	[29]
Mortality (all cause)	Life table
Cost per patient (US $) *
Total costs	126.04	68.46	Gamma	[26]
Total intervention	34.64	na	Gamma	[26]
Intensive training	28.66	na	Gamma	[26]
Peer support	5.04	na	Gamma	[26]
Phone calls	0.94	na	Gamma	[26]
Patient income loss	25.66	18.22	Gamma	[26]
Medical consultation	8.32	7.70	Gamma	[26]
Screening	28.62	26.86	Gamma	[26]
Medication	18.70	7.36	Gamma	[26]
Hospitalisation	5.60	2.90	Gamma	[26]
Utility (mean)*	0.86	0.84	Beta	[26]
Pre-diabetes^a	0.87	0.87	Beta	[26]
T2DM^a	0.90	0.86	Beta	[26]
Complications^a	0.85	0.79	Beta	[26]

^*Adopted from the six months trial data, costs were doubled to make an annual change
** cardiovascular disease events mortality;
^abased on the same trial data but calculated separately;
T2D Type 2 diabetes, SD Standard deviation, QALYs Quality-adjusted life years, RCT Randomised Control Trial evaluating the current examined health behaviour intervention in Nepal, na not applicable

ISSN: 1741-7015